H.C. Wainwright Reiterates Buy Rating on Rani Therapeutics Holdsing s (RANI)

October 18, 2024 6:46 AM EDT Send to a Friend
H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $9.00 price target on Rani Therapeutics Holdsing s (NASDAQ ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login